CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer

Launched by XINHUA HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Aug 25, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating how a new test that looks for circulating tumor DNA (ctDNA) can help doctors understand how well a specific treatment works for women with high-grade serous ovarian cancer. The study involves women who have been newly diagnosed and are starting their first treatment after chemotherapy, using a medication called PARP inhibitors. Researchers will collect blood samples from participants at various stages of their treatment to see if the presence of ctDNA can predict how effective the PARP inhibitors are and if it can help catch any signs of the cancer coming back early.

To be eligible for the trial, participants need to be at least 18 years old and have been diagnosed with advanced ovarian cancer that can be surgically treated. They must fully understand the study and agree to participate. During the trial, participants will be monitored closely, and their health data will be collected to help improve future treatments for ovarian cancer. This trial is currently recruiting participants, so if you or someone you know fits the criteria, it could be a valuable opportunity to contribute to important research.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Ovarian cancer first diagnosed and treated;
• • 2. Pathologically confirmed as epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer;
• • 3. The stage of the disease is II-IV, and surgery will be performed after evaluation;
• • 4. Age ≥ 18 years old;
• • 5. Subjects and their families fully understand the research plan and sign an informed consent form.
• Exclusion Criteria:
• • 1. Pathologically confirmed as non-epithelial ovarian cancer;
• • 2. Surgical treatment cannot be performed after evaluation;
• • 3. Malignant tumors found in other parts of the study were found within five years before enrollment or at the time of enrollment;
• • 4. Patients who do not agree to use clinical first-line targeted drugs;
• • 5. Severe mental illness;
• • 6. Severe cardiovascular disease, uncontrollable infection, or other uncontrollable comorbid diseases.